Table 4.
Drug Resistance Rates of P. aeruginosa Isolates from 2015 to 2017 (%)
| Antimicrobial Agents | 2015 (n=143) | 2016 (n=105) | 2017 (n=95) |
|---|---|---|---|
| Imipenem (IPM) (MIC: 8 µg/mL) | 15.4* | 26.7 | 13.8* |
| Meropenem (MEM) (MIC: 8 µg/mL) | 11.5* | 23.1 | 10.3* |
| Piperacillin (PIP) (MIC: 128 µg/mL) | 12.7 | 20.4 | 11.5 |
| Ciprofloxacin (CIP) (MIC: 4 µg/mL) | 7.1 | 10.8 | 5.3 |
| Levofloxacin (LVX) (MIC: 8 µg/mL) | 9.9 | 5.9 | 5.3 |
| Gentamicin (GEN) (MIC: 16 µg/mL) | 9.2 | 7.8 | 7.7 |
| Ceftazidime (CAZ) (MIC: 32 µg/mL) | 10.2 | 19.0 | 14.8 |
| Piperacillin/Tazobactam (TZP) (MIC: 128 µg/mL) | 9.9 | 12.5 | 8.6 |
| Cefepime (FEP) (MIC: 32 µg/mL) | 7.7 | 15.2 | 14.9 |
| Tobramycin (TOB) (MIC: 4 µg/mL) | 4.6 | 4.8 | 3.3 |
| Amikacin (AMK) (MIC: 64 µg/mL) | 2.8 | 5.8 | 3.3 |
Notes: Differences between proportions were analyzed using the χ2 test. *p<0.05 compared to resistance rates in 2016.